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Abstract—This work illustrates four different spectrophotometric methods for metformin (MET) and canagliflozin (CANA) quantification in their recently approved pharmaceutical with trade name Invokamet®. The
proposed methods are simple, definitive and accurate. Certain ensuing steps implementing zero spectra
and/or ratio and/or derivative spectra were applied. Via implementing spectrum subtraction method accompanied with constant multiplication, zero order spectra were obtained for these drugs followed by their determination at their correlated λmax at 237 and 290 nm for MET and CANA, respectively. Meanwhile, through
employing method of derivative subtraction the two drugs were obtained in their first derivative spectra and
quantified at 242.7 and 319.0 nm for MET and CANA, respectively. The suggested methods were inspected
via laboratory prepared (diverse ratios) mixtures and they were excellently applied for analysis of Invokamet®
tablets. Moreover, sample enrichment via spiking technique was elected for a pharmaceutical formulation
analysis containing CANA as a minor component. Accuracy, precision and specificity were between the valid
limits. Validation steps were done in accordance with the ICH guidelines. Also, statistical compression was
carried out between the obtained and reported results and no crucial divergence appeared.
Keywords: canagliflozin, metformin, SGLT2 inhibitors, Invokamet
DOI: 10.1134/S1061934820060180

Diabetes mellitus Type 2 (DMT2) is a big global
health issue, accounting for about 90% of the diagnosed cases of diabetes. The pervasiveness of DMT2 is
increasing globally at an alarming rate with an estimated increment to 552 million by 2030. Low- and
middle-income countries challenge the greatest threat
of diabetes with nearly 80% of all diabetes-related
fatality occurring in these countries [1].
In DMT2, combination of drugs not only reduces
the pill burden, which leads to better patient compliance, but also provides broader control of disease and
its complication. Invokamet® [2], a relatively new drug
combination, includes 1000/500 mg of metformin
hydrochloride and 50/150 mg of canagliflozin.
Metformin (N,N-dimethylimidodicarbonimidic
diamide, Scheme 1), a biguanide anti-hyperglycemic
drug, controls blood glucose levels by boost insulin
sensitivity and augmenting glucose uptake in the liver

[3]. It is widely adopted in the therapy of diabetes mellitus type 2.
Canagliflozin [4] ((2S,3R,4R,5S,6R)-2-[3-[[5-(4fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]6-(hydroxymethyl)-oxane-3,4,5-triol, Scheme 1) is a
sodium glucose co-transporter (SGLT2) suppressor
approved by the Food and Drug Administration for the
treatment of DMT2 in March 2013. SGLT2 inhibitors
reduce blood sugar by decreasing the reabsorption of filtered glucose in the kidneys resulting in raising glucose
excretion in urine.
Because CANA is considered to be a new drug, it
has no legitimate official method in any pharmacopoeia yet in contrary to MET which has an official
method of determination in both United States Pharmacopeia [5] and British Pharmacopeia [6].
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Scheme 1. Structures of metformin and canagliflozin.

Referring to the literature review, sparse chromatographic techniques were applied [7, 8] for simultaneous quantitation of CANA and MET in pharmaceutical preparations or in laboratory prepared mixtures.
Other few methods were found for determination of
CANA alone, either in dosage form [9–11] or in
plasma [12, 13]. On the contrary, various methodologies were developed for MET investigation using both
spectrophotometry and chromatographic techniques
[14–36].
Analysis of binary or ternary mixtures occasionally
requires an earlier separation before spectrophotometric analysis. So far, there have been methods used to
resolve those mixtures showing interfered spectra
like spectrophotometry methods with derivative
manipulations. Derivative techniques in spectrophotometry are considered to be effective for resolving the
interfered spectra and wipe out matrix interventions
[37–39].
The present study aims to provide easy, sensitive,
valid and precise analytical spectrophotometric methods for concurrent determination and quantification
of CANA as a minor component in presence of MET
in bulk and tablet forms with credible values of validation parameters.
THEORETICAL DESCRIPTION
OF THE METHODS
Spectrum subtraction accompanied with the constant multiplication method (SS–CM). This method
has been recently evolved for continuous resolution of
components in binary mixtures [40]. It is implemented by constant multiplication method and eradication of the retrieved zero order spectrum [41–43].
In case of X and Y mixture, Y is found to be more
extended than X so we can use spectrum subtraction to
erase Y followed by estimation of X. An advantage of
this technique is its suitability when sample enrichment is needed either with spiking or spectrum addition in case of small concentrations of Y or low absorptivity of one of the components in the extended part.
JOURNAL OF ANALYTICAL CHEMISTRY
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It can be expressed mathematically via dividing
mixture spectrum by a divisor (certain concentration
of the component which is more extended), new spectrum will be delivered as follows:

( X + Y )/Y ' = X /Y '+ Y /Y ',
( X + Y )/Y ' = X /Y ' + Constant,

(1)
(2)

to estimate the constant value from the (X + Y)/Y '
spectrum which is a straightforward parallel line to the
wavelength axis.
The first component (Y) can be concluded in constant multiplication method by multiplication of Y '
divisor by the already estimated constant Y/Y ', then we
get the D0Y curve as follows:

Y = Y /Y ' Y '.

(3)

By subtraction Y spectrum from zero order spectrum of the binary mixture (X + Y), X spectrum alone
is obtained. Then we get X concentration by referring
to the regression equation illustrating linearity
between each absorbance against concentration of X at
its λmax in zero order spectrum. The same is done to get
Y concentration using its corresponding regression
equation.
Derivative subtraction accompanied with the constant multiplication method (DS–CM). This is a
recently established technique for resolution of components in mixture analysis. It is applied for binary
mixtures like X and Y, where Y spectrum is found to be
more extended than X, so by using derivative subtraction we can eliminate the spectrum of Y when no effect
from the interfering one is observed. Another component which is less extended will be eliminated in its
first derivative [40–44].
This is used for components quantification in the
binary mixture by utilizing the constant multiplication
method for removing the obtained first order spectrum of the more extended drug. In case of the binary
mixture (X and Y), if Y is found to be more extended it
will be eliminated by first order spectrum subtraction
leading to determination of X. Via dividing the first
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derivative mixture spectrum obtained by the first
derivative of more extended Y ' (divisor), new spectrum is obtained as illustrated:

D /Dλ ( X + Y )/Dλ (Y ')
= D /Dλ ( X /Y ') + D/Dλ (Y /Y ') ,

(4)

D/Dλ ( X + Y )/Y ' = D/Dλ ( X /Y ') + Constant, (5)
to estimate the constant value from the D/Dλ(X +
Y)/Y ' spectrum which is a straightforward parallel line
to the wavelength axis.
The Y component is then calculated using constant
multiplication method by multiplying Y ' divisor with
the already estimated constant of D/Dλ(Y/Y '), then
the first derivative curves of Y can be obtained using
the following equation:

D/Dλ (Y ) = D /Dλ (Y /Y ') D/Dλ (Y ') .

(6)

The X component is then determined by subtracting D/Dλ(Y) spectrum from the first derivative curve
of the mixture, which results in first derivative curve
of X. X concentration is then computed using regression equation of the linear relationship between the
first derivative amplitudes at their λmax against the correlated concentrations.
First derivative spectrophotometry (D1). Derivative
spectrophotometry is broadly applied in the investigation of multicomponent mixtures with interfering
spectra. This eradicates overlapping from matrix via
applying the zero-crossing techniques [44]. Simultaneous determination of CANA (Y) and MET (X)
depending on the first derivative mode technique was
carried out. The first derivative spectra of these drugs
permitted individual and simultaneous determination
of CANA and MET in different concentration intervals by measuring the amplitude of one drug at zero
crossing point of the other. The concentrations of X
and Y were then established using linear regression
equations between the first derivative amplitudes at
λmax against the correlated concentrations of X and Y,
respectively.
Amplitude modulation method (AM). Application of
amplitude modulation method was done on the binary
mixture using an isoabsorptive point [45, 46] in zero
order spectrum. This in turn retained as an isoabsorptive wavelength in the ratio spectrum [47–49]. A normalized spectrum was equal to the divisor absorptivity
along the spectrum range. At these wavelengths the
resulted absorbances of the ratio spectrum were
adjusted to concentration values expressing each component concentration.In case of X and Y mixture, zero
order spectra showed that Y was found to be more
extended than X. Meanwhile X and Y spectra came
together at an isoabsorptive point (λiso).When it comes
to computing the modulated amplitude correlated to Y
concentration, it would be quantified from the spectrum of (X + Y)/Y ' that gave a straightforward line parallel to wavelength axis in the extended part of Y spec-

trum. The divisor used was normalized Y so it gave Y
concentration after division of the binary mixture. The
amplitudes retrieved from the ratio spectrum at the
isoabsorptive point gave concentrations of both Y and
X, so by subtracting the estimated value of the constant
from the ratio spectrum, amplitude referring to component X at λiso was steadily computed. To eradicate
any inaccuracy, the obtained X and Y concentrations
may be interchanged to the true concentrations via
utilizing merged equation of regression at

(7)
λ iso : cRec = Slopec ± Intercept,
where cRec is the adjusted amplitude at λiso and c corresponds to X or Y true concentration, the slope
approaches one and the intercept approaches zero.
EXPERIMENTAL
Device. BIO Double-beam UV-Vis spectrophotometer JASCO V-630 (S/N: C367961148) with
1.00 cm quartz cells was used in the scanning range of
200–400 nm and 0.1 nm intervals. Data manipulation
was done via Spectra Manager II software.
Chemicals and reagents. Metformin was graciously
obtained from Chemical Industries Development
(Cairo, Egypt), canagliflozin was purchased from
BaoJi Guokang Bio-technology co. (China). The
purities were certified to be 99.90 and 99.88% as
reported in certificates from suppliers for MET and
CANA, respectively. Invokamet® tablet labelled to
contain 1000 and 50 mg of MET and CANA, respectively, was manufactured by Ortho-McNeil-Janssen
Pharmaceuticals (USA). This dosage form was bought
from USA market. HPLC grade methanol was from
Fisher Scientific (Loughborough, Leicestershire,
UK).
Standard solutions. Stock standard solutions of
MET and CANA were prepared at 1 mg/mL in methanol. 100 µg/mL working standards were prepared for
both analytes by further dilution with methanol.
Procedures. 10 µg/mL MET and CANA solutions
were used to measure zero order absorption against
blank (methanol) in the range of 200–400 nm.
Construction of calibration graphs. Aliquots guaranteed to have 2–15 and 5–20 µg/mL of MET and
CANA, respectively, were solely prepared in methanol. These samples were used to measure zero order
and first derivative spectra (smoothing factor (Δλ) of
10 and scaling factor of 10). Results obtained were
stored in computer. Then, by relating the absorbance
in zero order spectra of MET and CANA at their λmax
of 237 and 290 nm, respectively, against the equivalent
concentrations calibration graphs were constructed.
Regression equations were then obtained separately
for each analyte.
For the first derivative spectra, calibration graphs
were constructed by relating the peak amplitudes of
MET and CANA at 242.7 and 319 nm, respectively, vs.
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the analogous concentrations of each of them. Regression equations were subsequently obtained.
Prepared mixtures. A series of MET and CANA
accurate aliquots were pipetted from working standards and added into 10 mL volumetric flasks. Six
mixtures with accurate diverse ratios of the studied
drugs were prepared. After completion to the volume
with methanol, spectra of each drug were measured
and recorded in range of 200–400 nm.
While applying amplitude modulation method,
cited drugs concentrations (MET and CANA) were
continuously computed using the recorded amplitudes
at 252.9 and 295.5 nm, respectively, on the same spectrum. A unified regression equation at λiso was constructed. This enabled to determine concentration of
each drug separately, while concentration determination in other methods could be achieved via substitution in the analogous regression equation of the
method.
Application to tablets. Ten Invokamet® tablets were
precisely weighed and efficiently powdered. A fixed
amount of this powder guarantying to have 100 mg of
MET was weighed and dissolved in methanol using
ultrasonic bath sonicator for 25 min. Then filtration
was done in another 100 mL volumetric flask followed
by completion to the mark with methanol. Aliquots of
MET and CANA were transferred accurately to a
10 mL volumetric flask to get a final mixture containing 10 and 0.5 µg/mL of MET and CANA, respectively. The concentration of CANA in a tablet mixture
was then enriched with 5 and 7 µg via spiking technique using pure standard of CANA prior employing
each proposed method.
RESULTS AND DISCUSSION
In order to resolve interfered spectra of more than
one compound in the mixture without preliminary
separation of the analytes, certain spectrophotometric
methods must be employed. Lately, these methods
have been greatly evolved and utilized. Mathematical
spectrophotometric analytical methods are quite
expedient over other analytical techniques or instrumentations like gas chromatography−mass spectrometry, liquid chromatography−nuclear magnetic resonance, liquid chromatography−mass-spectrometry,
etc. Those techniques are more complicated,
demanding continuous changes in conditions and precise optimization of such parameters as temperature,
flow rate, pH, etc. On the other hand, spectrophotometric techniques are easy to employ and operate,
fast, sensitive and surprisingly economical. While
developing these analytical methods, chemists focus
chiefly on how to implement new mathematical techniques. The most essential advantage in spectrophotometric techniques is their diversity and flexibility
according to conditions of each mixture, where the
JOURNAL OF ANALYTICAL CHEMISTRY
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analysts have the opportunity to apply the most convenient method for analysis and resolution.
The ratio of MET and CANA in the studied tablets
was 20 : 1, zero order spectra was found to be very hard
to determine the concentration of each compound
simultaneously, since low CANA concentrations were
out of the linearity range to attain this dosage content
form the ratio. Spectral properties of each drug, its
absorptivity and amount in the mixture restricted the
choice of the ideal concentration range.
In Fig. 1 CANA spectrum was found to be more
extended than MET spectrum. Canagliflozin showed
a peak at 290 nm while Metformin showed the highest
amplitude at 237 nm. Both CANA and MET showed
two isoabsorbative points at 223.9 and 252.9 nm,
respectively. The contribution of MET in all prepared
mixtures was higher than that of CANA mimicking the
provided pharmaceutical dosage form Invokamet®
(1000 and 50 mg of MET CANA, respectively).
CANA in the extended region exhibited slight absorbance at low concentrations, which in turn prevented
its direct determination in the combined dosage form.
Sample enrichment was chosen to be carried out to
maintain precise CANA quantification in the spectrum extended region that in turn showed much lower
absorptivity than other peaks. It was performed by
adding accurate known amounts of the minor drug
pure standards in the binary mixtures leading to its
precise determination simultaneously with MET.
Spectrum subtraction accompanied with multiplication of constant (SS–CM) or derivative subtraction
accompanied with multiplication of constant (DS–
CM) as well were successfully utilized for investigation
of CANA and MET binary mixtures. Generally, constant multiplication is considered to be a relatively new
tactic [47–49].
SS–CM mainly depends on employing the intelligent mathematical techniques that uses the constants
appearing in spectra of the mixture, and then by further developing the genuine spectrum of the overlapped component is obtained. In order to evaluate the
other drug content in combination, spectrum subtraction of the resolved component is carried out from the
initially used mixture. This method is used for both
quantification and resolution of two investigated
drugs in their binary prepared mixture. It differs
from the formerly used ratio subtraction method
which is applied only for resolution of the investigated
drugs [50].
This new spectrophotometric method has the
advantage of acquiring spectra of the two investigated
compounds after employing these resolution techniques. This leads to further determination of the
drugs at their λmax of 237 and 289 nm for MET and
CANA, respectively, in zero order spectra. Maximum
ranges of linearity and sensitivity were achieved, the
applied methods could be used in concentration
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Fig. 1. Zero order absorption spectra of 10 µg/mL canagliflozin (—) and metformin (--) using methanol as blank.

ranges of 2 and 2.5 µg/mL for CANA and MET,
respectively.
Consequently, upon tablet analysis CANA only
was enriched with the pure standard enabling its
simultaneous determination where there was no need
for MET enrichment. On the contrary, other applied
methods like amplitude modulation allow to quantify
each compound in mixture by choosing a standard
solution to act as divisor and a unified equation of
regression at the isoabsorptive point for accurate
determination of the two drugs in the laboratory prepared mixtures and tablets.
The presented methods were found to be very easy,
fast, simple and precise. The compounds under investigation can be determined and quantified either in
prepared mixtures or in the tablet dosage form. They
differ from other sophisticated techniques such as chemometric methods which need a particular software
(Matlab), diverse preparation of standard solutions
and various laboratory prepared mixtures with diverse
amounts of analytes. Not to mention HPLC methods
which also require more complicated optimization of
conditions.
Spectrum subtraction accompanied with constant
multiplication. CANA was found to be more extended
than MET in zero order absorption spectrum as shown
in Fig. 1.
To apply this method, first step is dividing laboratory prepared mixture spectrum (Fig. 2a) with a
selected concentration of CANA as the divisor spectrum that represents pure CANA standard (5 µg/mL).
A straightforward line parallel to the wavelength axis in
the region extended in spectrum (CANA/CANA’)
(270–320 nm) is obtained (Fig. 2b). Then, upon multiplying the value of this constant by the initially used
divisor spectrum of CANA original CANA curve in
the zero order is obtained. Corresponding absorbance
is measured at λmax of 289 nm (Fig. 2c).

To evaluate CANA concentration, substitution of
the absorbance value in the corresponding linear
regression equation between the absorbance and
CANA concentration was performed.
Finally, by subtracting the obtained zero order
CANA spectrum from the corresponding laboratory
mixture the D0 spectrum of MET was obtained
(Fig. 2d). Subsequently, determination of MET concentration via substitution in its corresponding regression equation constructed between concentration and
its correlated absorbance at λmax of 237 nm was
achieved.
By employing the spectrum subtraction method for
components resolution, we obtained the genuine
spectrum of each component with no interferences
from the other one. Therefore, using this method is
beneficial in determining the two drugs at their λmax.
In addition, the regenerated spectra can be considered
as a spectral profile.
Derivative subtraction accompanied with constant
multiplication. While analysis of the prepared mixtures
possessing high ratio of MET by implementing spectrum subtraction accompanied with constant multiplication technique two changes were observed.
Firstly, contribution of MET was raised, secondly, the
extended part changed to very small. This resulted in a
boisterous constant and accordingly the constant
determination in the plateau area turned out to be
tougher resulting in imprecise constant values and
afterwards imprecise recoveries of the unscathed
CANA. Derivative subtraction accompanied by constant multiplication offers a solution for this error.
To efficiently employ the first derivative method,
initially various scaling and smoothing factors were
tried. Smoothing factor of 10 and scaling factor of
10 gave the best ratio between signal and noise with
good spectra resolution. Figure 3 showed the overlaid
D1 spectra of the two components.
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Fig. 2. Zero order absorption spectra of laboratory prepared mixtures with different canagliflozin (CANA) and metformin (MET)
concentrations (a); CANA (5 µg/mL) as a divisor showing constants in the plateau region (b); different CANA (5–20 µg/mL)
concentrations after constants multiplication by a divisor of CANA (5 µg/mL) (c); different MET (2–15 µg/mL) concentrations
after subtraction of CANA zero order absorption spectra (d).

To enhance the sensitivity, derivative subtraction
accompanied with constant multiplication method
was employed to get the D1 spectrum of one component with no interference from the other one in the
tablet dosage form or prepared mixture. In this work
the amplitudes were measured at zero crossing points
of 319 and 242.7 for CANA and MET, respectively.
The concentrations of CANA and MET were then
computed via regression equations of the linear relationship between the peak amplitudes against the correlated concentrations of CANA and MET.
The divisor concentration of 5 µg/mL was chosen
for CANA that offered perfect results concerning the
average percentage recovery and it was compromised
regarding noise and sensitivity.
The constant value was obtained by dividing the
first derivative spectrum of the laboratory prepared
mixtures (Fig. 4a) by a divisor spectrum (first derivative spectrum of 5 µg/mL standard CANA solution).
The constant was obtained from the straight line
JOURNAL OF ANALYTICAL CHEMISTRY
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which was parallel to wavelength axis in the spectrum
extended part (292–328 nm) as shown in Fig. 4b. By
multiplication with the divisor spectrum, we got the
spectrum that represented the first derivative curve of
CANA (Fig. 4c). Subtracting the first derivative spectrum of CANA from the first derivative spectrum of
the mixture resulted in obtaining the D1 spectrum of
MET (Fig. 4d). The concentrations of CANA and
MET were then evaluated via their corresponding
equations with linear relationships between the peak
amplitudes and the correlated concentrations.
Derivative subtraction coupling with constant multiplication and ordinary derivative subtraction are only
utilized in case of the noisy constant when measuring
zero order spectra. A noisy constant prevents accurate
application of the method and unsatisfactory recoveries are further obtained. In addition, like other methods that utilize the derivative technique, DS–CM has
the advantage of enhanced peaks leading to a precise
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determination and quantification of the constants
resulting in good final recoveries.
Amplitude modulation method. This technique
relies on the presence of an isoabsorptive point in the
overlaid spectra of both components. This point will
be preserved with no change in spite of the division by
a certain chosen divisor. The results obtained were
markedly influenced by the divisor change. Therefore,
to get rid of the consequences of choosing wrong divisor, normalized CANA spectra that exhibited the
absorptivity of CANA at various wavelengths were
used.
Firstly, the binary mixture spectrum was divided by
the normalized CANA spectrum as a divisor. A ratio
spectra was obtained showing a constant in the plateau
area (275–316 nm) that in turn was equivalent to
CANA constant amplitude over any region in the
spectrum. The amplitude of the ratio spectra at this
isoabsorpative point (252.9 nm) was equivalent to the
summation of CANA and MET responses. Ratio
mathematical handling via normalized divisor result-

ing in the changeover of CANA curve to a constant
showed as a straightforward line parallel to axis of
wavelength with no change in the amplitude value corresponding to CANA concentration. By subtracting
the already concluded constant from the mixture
amplitude at λiso of 252.9 nm, MET amplitude was
found:

Pmix at 252.9 nm = PMET at 252.9 nm + Constant.(8)
PCANA at 252.9 nm is the estimated constant in the plateau area between 275–316 nm and it is considered to
be the concentration of CANA.

PMET at 252.9 nm = Pmix at 252.9 nm
− PCANA at 252.9 nm.

(9)

PMET at 252.9 nm is the estimated amplitude at
252.9 nm considered to be the recorded concentration
of MET.
The substantive values represented CANA and
MET concentrations which were further computed by
using a corresponding unified regression equation at
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Fig. 3. Overlaid first derivative spectra of 10 µg/mL canagliflozin (—) and metformin (---) using methanol as blank.
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Fig. 4. First derivative absorption spectra of lab prepared mixtures with different canagliflozin (CANA) and metformin (MET)
concentrations (a); CANA (5 µg/mL) as a divisor showing constants in the plateau region (292–382 nm) (b); different CANA
concentrations (5–20 µg/mL) after constants multiplication by a divisor of CANA (5 µg/mL) (c); different MET concentrations
(2–15 µg/mL) after subtraction of CANA first derivative absorption spectra (d).
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252.9 nm. This was performed to get rid of any flows
related to signal to noise:
(10)
crec = 1.002c + 0.002.
Method validation. These applied spectrophotometric resolution and quantification methods were
fully validated and certified in consonance with the
ICH guidelines [51] as represented in Table 1. The
analysis of laboratory prepared mixtures containing
differing ratios and amounts of the two drugs gives
adequate and accurate values regarding each method
specificity and calibration range as represented in
Table 2. Further investigation was done via employing
those methods to the quantification of the two cited
drugs in Invokamet® tablets. Rationality, viability and
sustainability of reported techniques were further estimated via the standard addition application (Table 2).
Results of statistical comparison and validation. Statistical comparison and validation of the obtained
results were done via comparison with the literature
methods [9, 24]. Calculated t and F values were tested.

They were found to be lower than the corresponding
theoretical values. This proved that no notable differences were between the investigated and the reported
methods regarding accuracy and precision (Table 3).
CONCLUSIONS
In this work new, simple and smart spectrophotometric methods were utilized and fully presented for
concurrent determination and quantification of
CANA and MET in their mixtures. To investigate
binary mixtures with the lowest number of steps, spectrum subtraction and derivative subtraction methods
have been applied. These two techniques have the
main advantage of their applicability in mixture analysis when one overlapped component has a noted contribution in the extended area in the spectrum while
measuring the constant value. Using the derivative
technique leads to the complete elimination of this
contribution. When derivative resolution accompanied with constant multiplication is employed, the
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Table 1. Assay parameters and method validation by applying the proposed spectrophotometric methods for determination
of canagliflozin and metformin
CANA
Parameter

MET

SS–CM

DS–CM

D1

AM

SS–CM

DS–CM

D1

AM

RSDa, %

5–20
0.050
99 ± 1
0.030
0.9999
1.31

5–20
0.0214
99.6 ± 0.9
0.014
0.9999
1.10

5–20
0.0216
100 ± 1
0.015
0.9998
1.72

5–20
0.0507
100 ± 1
0.034
0.9999
1.26

2–15
0.0791
100.7 ± 0.8
0.012
0.9999
2.57

2–15
0.0422
99 ± 1
0.002
0.9999
2.19

2–15
0.0427
99 ± 2
0.006
0.9999
1.25

2–15
0.0776
100 ± 2
0.007
0.9999
1.95

RSDb, %

1.46

0.81

0.42

1.51

1.91

1.38

1.11

1.42

Linearity, µg/mL
Slope
Accuracy, %
Intercept
Correlation coefficient

a Intra-day relative standard deviation of CANA (5, 10, 15 µg/mL) and MET (3, 6, 9 µg/mL) (n = 3), b inter-day relative standard devi-

ation of CANA (5, 10, 15 µg/mL) and MET (3, 6, 9 µg/mL) (n = 3).

Table 2. Determination of canagliflozin and metformin in laboratory prepared mixtures and the pharmaceutical dosage
form by the proposed methods and results obtained by the standard addition techniques
Recoverya, %
Concentration, µg/mL
SS–CM
CANA
5
10
20
10
6
5
Mean, %
SD

MET
10
2
5
15
8
15

CANA

MET

D1

DS–CM
CANA

MET

CANA

AM
MET

Lab prepared mix
98.3
99.8
98.7
101.5
98.9
100.1
97.9
99.9
98.7
100.2
98.0
100.2
97.5
101.4
100.5
99.3
101.2
97.8
100.8
101.8
99.2
98.5
101.1
99.0
99.6
100.5
100.5
99.6
101.3
94.9
101.0
100.6
100.9
99.8
99.9
100.4
99.2
100.7
99.7
99.8
100.1
98.7
1.49
0.82
0.99
1.01
1.39
2.12
Invokamet tablet (1000 mg of MET/50 mg of CANA)
97.3
100.7
97.1
100.8
102.9
98.5

CANA

MET

100.9
101.9
98.4
98.3
99.3
98.7
99.5
1.46

97.8
101.2
98.9
98.0
102.0
101.4
99.9
1.85

101.9

99.4

99 ± 1
100.8

101.4 ± 0.8
97.8

10/0.5 + 5 pure addedb
Mean ± SD
97.29 ± 0.03 97.6 ± 0.7 101.4 ± 0.8 97.29 ± 0.03
b
97.7
100.9
98.1
101.2
10/0.5 + 7 pure added

99.1 ± 0.8
100.6

Mean ± SD

100.2 ± 0.3 99.6 ± 0.4 100.3 ± 0.5

a

98.0 ± 0.3

Average of three determinations,
flozin.

b the

99 ± 1

98.4 ± 0.5

100 ± 2

102 ± 2
99.6

99 ± 1

ratios present in the pharmaceutical formulations spiked with known pure amounts of canagli-

resulting spectrum obtained is the first derivative of
any component equal to that of pure compound with
no other components overlapping in the mixture.
Derivative spectra of any of the two cited drugs would
be obtained directly at a fixed particular zero crossing
wavelength. Another method using the isoabsorpative
point in ratio spectra is the amplitude modulation
method employed for both resolution and quantification. This method offers the advantages of minimum
mathematical intervention and no need for complementary methods. Sample enrichment via sample
spiking was adopted to reveal accurate results. The
JOURNAL OF ANALYTICAL CHEMISTRY
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ease, accuracy, rationality and validity of those represented methods not needing any particular program
for data manipulation make them possible to be used
in routine determination of cited drugs in their original
pharmaceutical dosage forms in quality control laboratories.
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Table 3. Statistical comparison of the proposed methods and the reference method for canagliflozin [9] and metformin
[24] determination
Proposed method
Value

D1

SS–CM

Reported method

DS–CM

AM

CANA

MET

CANA

MET

CANA

MET

CANA

MET

Student’s t-testa (2.571)

99.2
1.49
1.49
5
2.22
0.468

100.7
0.82
0.82
5
0.67
0.155

100.1
1.39
1.39
5
1.93
0.762

98.7
2.11
2.11
5
4.45
2.007

99.6
0.87
0.87
5
0.76
0.155

99.5
1.24
1.24
5
1.54
1.706

99.5
1.46
1.46
5
2.13
0.014

99.9
1.85
1.85
5
3.42
0.786

F-valuea (6.388)

3.844

1.025

3.345

6.786

1.310

2.344

3.690

5.216

Mean
SD
RSD, %
n
Variance

CANA

MET

99.5
0.76
0.76
5
0.58

100.6
0.81
0.81
6
0.66

a The values in the parenthesis are the corresponding theoretical values of t and F at P = 0.05.
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